Semaglutide, Tirzepatide, and Orforglipron: What Can Actually Be Compared?

Few therapeutic classes have generated as much public confusion as incretin-based obesity drugs. Semaglutide, tirzepatide, and the emerging oral agent orforglipron are frequently discussed as if they were interchangeable options on a single ladder of efficacy. They are not. Understanding what can actually be compared requires separating drug mechanisms from trial designs, and resisting the temptation to rank therapies using numbers pulled from fundamentally different studies.

Three drugs, two mechanisms, one delivery gap

Injectable semaglutide is a GLP-1 receptor agonist, while injectable tirzepatide targets both GLP-1 and GIP receptors. Orforglipron is a small-molecule oral GLP-1 receptor agonist. The FDA approved it as Foundayo on April 1, 2026, for chronic weight management in eligible adults, making route of administration a practical difference rather than an investigational-versus-approved divide.

The oral route removes injections and, according to the FDA labeling, Foundayo does not carry food or water timing restrictions. Convenience, efficacy, tolerability, cardiovascular evidence, access, and cost remain separate questions; one cannot be inferred from another.

The head-to-head problem

The central limitation in any comparison of these three drugs is structural. No single randomized trial directly compares all three. This means that any attempt to build a definitive league table of weight-loss percentages is methodologically flawed from the start. Cross-trial comparisons are routinely circulated in media coverage and patient forums, but they pool results drawn from unlike populations, administered at different doses, over different durations, and under different trial designs.

A weight-loss figure reported in a semaglutide trial cannot be cleanly placed beside a figure from a tirzepatide trial and read as a direct measure of superiority. Baseline body mass index, supportive behavioral interventions, titration schedules, and patient exclusion criteria all vary. When these variables differ, the resulting percentages reflect the specific conditions of each trial, not a universal pharmacological ranking.

What the evidence does support

Direct three-way comparison remains impossible. Semaglutide, tirzepatide, and orforglipron each have randomized evidence supporting approved weight-management uses, but their pivotal programs used different populations, doses, durations, estimands, and comparators. A separate head-to-head trial compared tirzepatide with semaglutide, while other trials examined orforglipron against placebo or in maintenance designs. Those datasets answer different questions.

FDA approval establishes that orforglipron met the agency’s benefit-risk standard for its labeled use. It does not create a direct efficacy ranking against semaglutide or tirzepatide, and later comparative or outcomes studies may answer questions the approval trials were not designed to resolve.

Why rankings mislead

The temptation to rank these drugs by headline weight-loss percentage is understandable but analytically unsound. A comparison that places tirzepatide above semaglutide, or semaglutide above orforglipron, based on non-head-to-head data assumes that the only variable is the molecule. In reality, the trial environment is a variable. Duration alone can dramatically shift reported outcomes: a longer trial may capture more weight loss, but it may also capture more treatment discontinuation, which affects the final reported average.

Additionally, efficacy is not a single dimension. Weight loss is the most reported metric, but tolerability, gastrointestinal side effects, long-term safety, cardiovascular outcomes, and cost all factor into therapeutic value. A drug that produces marginally more weight loss but causes significantly higher rates of discontinuation may not represent a clinically superior option for a given patient population.

Regulatory and practical context

Regulatory status no longer separates the three in the United States: all have approved weight-management indications. The remaining comparison problem is evidentiary. Approved labels can differ, and trial results cannot be treated as interchangeable simply because the drugs now share a broad treatment category.

The most accurate comparison starts with the question being asked. Tirzepatide and semaglutide have direct head-to-head evidence; orforglipron offers an approved oral option supported by its own program. A definitive three-drug ranking would still require a trial using matched populations, treatment goals, durations, and analysis methods.